FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
about
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinomaPalliative chemotherapy for advanced gastric cancer.Weekly chemotherapy in advanced prostatic cancerWeekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.Chemotherapy for gastric cancer.Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerEffective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancerManagement of carcinomas of the upper gastrointestinal tract.Chemotherapy for advanced gastric cancer: review of global and Japanese status.Advanced gastric cancer: an update and future directionsEvolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers.Chemotherapy for advanced gastric cancer: slow but further progress.Pre-operative chemotherapy for gastric cancer.Systemic therapy for advanced gastric cancer: a clinical practice guideline.Global chemotherapy development for gastric cancer.Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.Mitochondrial protein 18 (MTP18) plays a pro-apoptotic role in chemotherapy-induced gastric cancer cell apoptosis.Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.Implications of therapy-induced selective autophagy on tumor metabolism and survival.Curing gastric cancer--hone the scalpel with magic?Schedule-dependent combined sensitivity testing of anti-cancer agents in human gastric carcinoma cell lines.A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.
P2860
Q33361500-B3B62380-0C75-4005-9E0B-CD069C331EE4Q33366008-CF8E0625-1BAA-4943-B823-64E43EC82A2FQ33389160-E2D34CF2-C5D9-4EFD-9311-B758920BBBF5Q33488159-BFB804AA-3540-45E7-8511-6A9143FCA690Q33490610-63562291-3668-468B-8F7B-8E0F76E8A080Q33503301-4AE51678-24E9-444C-B835-2B8E957D0A9AQ34852173-ED9895BB-9E3B-44FD-9413-70460D0CE202Q35034753-43660E8D-5334-48B2-A092-9A0DF1C9CBEBQ35936039-3D2780F1-781B-498E-8900-CB36445C4817Q35977021-82138C26-9BCF-4B21-BFAB-16F7B91FF0BEQ36292847-6487F09B-EFF3-471A-A6FF-36BB7EB01325Q36398226-6A53695D-F7CF-4A1C-B11E-F301296C94FAQ36625990-4804E01A-B1B9-4565-9D87-A06C5DACAF79Q36642170-E39A4C75-6E16-4063-9EFD-F1B9FF1A155AQ36644681-98CAD8FA-4A74-4BAF-BE73-119B6BED2063Q36673543-B58AABED-1DC7-4748-B074-56D3B5C07649Q36748415-E1F4C910-B28E-48E4-91CB-BCDD7145D8CBQ37076553-2E6ACFCE-75DD-471E-9B34-6F97110CB8DCQ37141665-FE67E5D5-FAB8-4868-A422-8E7D91DABC73Q37141674-8E7A4387-F5C3-4D9C-B359-BFB19355E671Q37446941-73AB5E72-D8FB-4524-BBE5-1ACA4511819BQ37636574-62D83102-9F85-41E1-A121-DAD6C3308EEAQ37923311-94D341CF-2F32-401C-8F40-EBBE88ED5226Q38813532-465906B2-C9BB-4515-A9A7-B0DCC794BE6EQ41044387-F03BBDD0-E638-46A7-A06F-AEFC48CD0427Q41345691-EB991255-DBBA-4159-A985-368EB7DC2B6FQ42285544-E473F1BB-52C6-415C-B1B7-5DEB1083E1A5Q42541156-0015D77E-CE79-437A-9B4A-36DEB65B9B1BQ42715710-E80A361D-3B0A-4554-A8B7-055D21165D5AQ43686890-860872A1-C28E-48B9-99FA-4745059A8BF6Q44180988-ABF06508-E534-4817-895B-BF752E91FC8AQ44258498-67BB222C-FDAF-4A0B-88F6-10230FC62259Q45154773-ED6F66D1-F306-4FA9-932A-32CCBB3706EFQ53579494-51756559-E518-466B-A6FE-2FD2C7492EBFQ54139402-A1FBD294-27BF-4CFD-A4E4-353F7BC31BE1
P2860
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.
@ast
FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.
@en
type
label
FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.
@ast
FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.
@en
prefLabel
FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.
@ast
FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.
@en
P2093
P1476
FAMTX versus etoposide, doxoru ...... nment trial in gastric cancer.
@en
P2093
C Lightdale
D Niedzwiecki
V Vinciguerra
P304
P356
10.1200/JCO.1992.10.4.541
P407
P577
1992-04-01T00:00:00Z